Texcell Doubles Capacity for Biosafety Testing and Viral Clearance Studies

Texcell – North America, Inc., part of the Texcell Group of global biosafety contract research organizations, broke ground for a new facility in Frederick, MD. The expansion is a next step in Texcell's growth trajectory as they increase capabilities for all their service lines, including customized R&D cell culture, GLP viral clearance studies, and select GMP assay capabilities for viral safety testing. The multimillion-dollar facility will add 27,000 sq.-ft. of lab and office space, more than doubling current capacity for biosafety testing and viral clearance studies. The completion date is projected for 1Q23.
The new facility will have eight new independent client suites, specifically designed to be flexible based on the needs of the project and the client. The suites will be stocked with mobile equipment, such as new ÄKTA pure chromatography systems and nanofiltration units, that can be transferred from suite to suite as necessary. At this GLP facility, clients will have the opportunity to execute scaled-down manufacturing models, or have the work transferred to a dedicated viral clearance team.
"Viral clearance and safety testing are an integral part of the development of biologics and genetherapies. This expansion will give us the opportunity to scale up our testing capabilities to meet the rising demand for these life-saving products," said Jeff Schubert, President of Texcell – North America. "As the number of candidate molecules in clinical pipelines continues to grow rapidly, this additional capacity permits us to provide research support to even more clients, with the hallmark devotion and expertise that our technical team has become known for."